Details
August 4, 2020
12:00-1:00PM
XPOVIO® (selinexor) The first and only FDA-approved oral selective nuclear export inhibitor in relapsed refractory multiple myeloma (RRMM)
Hosted by Karyopharm
WEBINAR
Event Information
XPOVIO® Prescribing Information
Printer-Friendly Version
2020-08-04
2020-08-04 13:00:00
America/Detroit
XPOVIO® (selinexor) The first and only FDA-approved oral selective nuclear export inhibitor in relapsed refractory multiple myeloma (RRMM)
Event Information
XPOVIO® Prescribing Information
WEBINAR